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BACKGROUND
METHODS
Twenty right-handed male participants with schizophrenia or schizoaffective
disorder were administered intranasal oxytocin 40UI or placebo in a double-
blind, placebo-controlled, cross-over fashion during two visits separated by
7 days.
Participants engaged in a free-viewing eye-tracking task, looking at images
of Caucasian men displaying angry, happy, & neutral facial expressions and
control images including animate and inanimate stimuli.
Social cue processing, particularly face perception, plays a critical role in
social cognitive functioning. Patients with schizophrenia struggle to extract
information from faces and interpret facial expressions (Kohler et al., 2010).
Indeed, eye-tracking studies have demonstrated that schizophrenia patients
exhibit reduced exploratory behaviour (i.e. reduced number of fixations and
longer fixation duration) in response to facial stimuli compared to healthy
controls (e.g. Manor et al., 1999), suggesting restricted visual attention. The
neuropeptide, oxytocin has been demonstrated to exert pro-social effects
on behaviour and modulate eye gaze during face perception. In this study,
we tested whether oxytocin has a compensatory effect on visual processing
of human faces.
RESULTS
DISCUSSION
Figure 1. Examples of facial and control stimuli
Repeated-measures ANOVA were carried out to explore the within-subject
effects of treatment (oxytocin vs. placebo), stimuli (angry / happy / neutral /
animate / inanimate), and the interactions between stimuli and treatment
(p < .05, two-tailed).
Total number of fixations: Main effect of treatment (F1,17 = 5.604, p =
.030); Main effect of stimuli (F4,68 = 5.008, p = .001).
Duration of fixation: Main effect of treatment (F1,13 = 4.791, p = .047);
Main effect of stimuli (F4,52 = 1.382, p = .253).
Dispersion: No main effect of treatment; Main effect of stimuli (F4,68 =
2.998, p = .024).
Saccade amplitudes: No main effect of treatment; Main effect of stimuli
(F4,68 = 0.289, p = .008).
None of the interactions reached significance.
Figure 2. Mean Number of Fixations on Oxytocin vs Placebo
Figure 3. Mean Durations of Fixations on Oxytocin vs Placebo
In this study, oxytocin enhanced exploratory viewing behaviour by increasing
the total number of fixations, whilst reducing the mean duration of fixations
compared to placebo. These results indicate that acute administration of
intranasal oxytocin has the potential to enhance visual attention and improve
social cognitive deficits in schizophrenia (Averbeck et al., 2012). The absence
of any interaction effects may warrant future studies into oxytocin-induced
eye movement changes and facial emotion recognition in larger samples.
Primary outcomes:
1) Total number of fixations
2) Mean duration of fixations
Secondary outcomes:
3) Dispersion
4) Saccade amplitudes
